sST2 Biomarker Level in Acute/Chronic Coronary Syndrome After Revascularization (ST2)
The Effect of Cardiac Ischemia and Percutaneous Coronary Intervention on the Changes of sST2 Level
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alkhateeb
- Phone Number: +201023858689
- Email: areejalkhateeb@med.svu.edu.eg
Study Locations
-
-
-
Qinā, Egypt
- Recruiting
- South Valley University
-
Contact:
- Alkhateeb
- Phone Number: +201023858689
- Email: areejalkhateeb@med.svu.edu.eg
-
Principal Investigator:
- Areej AA Tammam Alkhateeb, MD, PhD
-
Qinā, Egypt, 83523
- Recruiting
- South Valley University Hospital
-
Contact:
- Areej AA Alkhateeb, Msc
- Phone Number: +201023858689
- Email: areejalkhateeb@med.svu.edu.eg
-
Principal Investigator:
- Areej AA Tammam Alkhateeb, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patients aged 40 years or more and have the risk factors of ischemic heart disease (IHD) with coronary artery disease symptoms will be included.
- For control subjects should be aged ≥ 40 years old with IHD risk factors including DM and HTN and without any symptoms or signs of cardiac ischemia.
Exclusion Criteria:
- Any patient with heart failure (EF <50%), any patients with rhythm abnormalities including atrial fibrillation, obese patients, structural heart diseases, uncontrolled chronic diseases such as hypertension or diabetes mellitus, any pulmonary artery or parenchymal diseases up to respiratory failure, acute systemic infection or inflammation, and chronic/acute renal diseases.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
single vessel diseased patients
sST2 level will be withdrawn at the baseline and after successful PCI
|
Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases.
The severity of stenosis will be done by modified gensini score from angiogram.
An sST2 ELIZA test will be done after withdrawal of the cases' samples.
|
|
2 vessels diseased patients
sST2 level will be withdrawn at the baseline and after successful PCI
|
Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases.
The severity of stenosis will be done by modified gensini score from angiogram.
An sST2 ELIZA test will be done after withdrawal of the cases' samples.
|
|
multivessels diseased patients
sST2 level will be withdrawn at the baseline and after successful PCI
|
Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases.
The severity of stenosis will be done by modified gensini score from angiogram.
An sST2 ELIZA test will be done after withdrawal of the cases' samples.
|
|
non-ischemic control patients
sST2 level will be withdrawn at the baseline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sST2 biomarker level
Time Frame: 24 hours before intervention
|
baseline comparison between ischemic heart disease and non-ischemic heart disease-control groups
|
24 hours before intervention
|
|
sST2 biomarker level
Time Frame: 48 hours post percutanous coronary intervention
|
follow up of only ischemic heart disease groups of sST2 level changes after intervention
|
48 hours post percutanous coronary intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SVU2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.